Hudson Bay Capital Management LP Halozyme Therapeutics, Inc. Transaction History

Hudson Bay Capital Management LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 12, 2020	SELL	$16.25 - $26.81 $2.19 Million - $3.62 Million	-135,000 Closed	0 $0
Q1 2020 May 14, 2020	SELL	$13.9 - $21.83 $695,000 - $1.09 Million	-50,000 Reduced 27.03%	135,000 $2.43 Million
Q4 2019 Feb 12, 2020	BUY	$14.93 - $19.53 $146,314 - $191,394	9,800 Added 5.59%	185,000 $3.28 Million
Q3 2019 Nov 13, 2019	BUY	$15.2 - $17.69 $3,040 - $3,538	200 Added 0.11%	175,200 $2.72 Million
Q2 2019 Aug 14, 2019	BUY	$14.75 - $17.26 $442,500 - $517,800	30,000 Added 20.69%	175,000 $3.01 Million
Q4 2018 Feb 13, 2019	BUY	$13.33 - $18.66 $1.93 Million - $2.71 Million	145,000 New	145,000 $2.12 Million

543

125M

294K

180K

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.62B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Hudson Bay Capital Management LP with notifications on news.